Status:

ACTIVE_NOT_RECRUITING

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Lead Sponsor:

Intellia Therapeutics

Collaborating Sponsors:

Regeneron Pharmaceuticals

Conditions:

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Eligibility:

All Genders

18-90 years

Phase:

PHASE3

Brief Summary

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Detailed Description

This is a multinational, multicenter, double-blind, placebo-controlled study in approximately 1200 participants, who will be randomized to receive a single infusion of either NTLA-2001 or placebo.

Eligibility Criteria

Inclusion

  • Documented diagnosis of ATTR amyloidosis with cardiomyopathy
  • Medical history of heart failure (HF)
  • Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention
  • Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL

Exclusion

  • New York Heart Association (NYHA) Class IV HF
  • Polyneuropathy Disability score of IV (confined to wheelchair or bed)
  • Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
  • History of active malignancy within 3 years prior to screening
  • RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed
  • Initiation of tafamidis or acoramidis within 56 days prior to study dosing
  • Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2
  • Liver failure
  • Uncontrolled blood pressure
  • Unable or unwilling to take vitamin A supplementation for the duration of the study

Key Trial Info

Start Date :

December 13 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2028

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT06128629

Start Date

December 13 2023

End Date

April 1 2028

Last Update

December 2 2025

Active Locations (126)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 32 (126 locations)

1

University of Arizona

Tucson, Arizona, United States, 85724

2

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

3

Western Greater Los Angeles VA Medical Center

Los Angeles, California, United States, 90073

4

Stanford University

Palo Alto, California, United States, 94305